Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access

scientific article published on 15 July 2010

Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1600-6143.2010.03191.X
P698PubMed publication ID20636451
P5875ResearchGate publication ID45268972

P50authorDorry SegevQ23881945
P2093author name stringA L Singer
R A Montgomery
A A Zachary
J E Locke
B E Lonze
C E Simpkins
N N Dagher
P2860cites workRadiologic placement of tunneled hemodialysis catheters in occluded neck, chest, or small thyrocervical collateral veins in central venous occlusionQ31846137
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectpatientQ181600
P304page(s)2154-2160
P577publication date2010-07-15
P1433published inAmerican Journal of TransplantationQ4744273
P1476titleEculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access
P478volume10

Reverse relations

cites work (P2860)
Q37990988Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale
Q38206175Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options
Q38392458Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management
Q38126085B-cell regulation and its application to transplantation
Q45178704Case Report: Successful Living Donor Kidney Transplantation in a Highly Human Leukocyte Antigen-Sensitized Recipient With a Positive Cytotoxic Crossmatch Using Bortezomib-Based Desensitization Without Intravenous Immunoglobulin
Q38609238Complement inhibition as potential new therapy for antibody-mediated rejection.
Q35567841Complement involvement in kidney diseases: From physiopathology to therapeutical targeting
Q58120548Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseases
Q26829789Current state of renal transplant immunosuppression: Present and future
Q47440056De novo thrombotic microangiopathy after kidney transplantation
Q51278476Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report.
Q38914719Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature.
Q33395870Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report
Q33396637Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation
Q52888455Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation.
Q55409568Evaluating the Use of Bortezomib and Eculizumab in Desensitization of Transplant Patients.
Q38144106Impact of donor-specific antibodies in reconstructive transplantation
Q38006827Innovative strategies in living donor kidney transplantation
Q37446883New immunosuppressive agents in pediatric transplantation
Q48272177Nontraditional sites for vascular anastomoses to enable kidney transplantation in patients with major systemic venous thromboses
Q38176005Novel immunosuppressive agents in kidney transplantation
Q39968188Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field
Q24599629Paroxysmal nocturnal hemoglobinuria from bench to bedside
Q45736192Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody
Q37888770Targeting B cells and antibody in transplantation
Q47443910The lack of Lazarus effect with proteasome inhibition
Q33406570The use of eculizumab in renal transplantation
Q58754943Thrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease
Q37952349Transplant accommodation--are the lessons learned from xenotransplantation pertinent for clinical allotransplantation?
Q27021397Treatment options and strategies for antibody mediated rejection after renal transplantation
Q35790601Utility of HLA Antibody Testing in Kidney Transplantation

Search more.